← Back to Home

Releasing the Brakes on Natural Killer Cells: Zumutor’s Cancer Antibody Moves Toward Combination Testing

ZM008 aims to relieve tumor-mediated suppression of natural killer cells and is being combined with a PD-1 antibody. Early human studies have begun, but more complete clinical evidence is needed to establish whether immune activation can actually extend patients’ lives.

By SURL BioNews

One reason solid tumors can evade immune attack is that they send immune cells signals to “stop attacking.” ZM008, an antibody being developed by Zumutor Biologics, aims to block one of these signals and restore natural killer cells’ anticancer activity. The program has entered a Phase 1 human trial in the United States and has begun exploring its potential use with an existing immunotherapy.

Natural killer cells (NK cells) integrate activating and inhibitory signals on their surface to determine whether to launch an attack. ZM008 is a fully human IgG1 monoclonal antibody targeting LLT1, also known as CLEC2D. According to the mechanism of action proposed by the company, it blocks the interaction between LLT1 on tumor cells and the CD161 receptor on NK cells, releasing an immune brake. Patients receive an antibody drug; the treatment does not involve collecting, modifying, and reinfusing NK cells.

Zumutor announced in June 2024 that the first patient had received ZM008. This first-in-human study, numbered NCT06451497, uses an open-label, dose-escalation design and enrolls patients with advanced solid tumors who have run out of standard treatment options. Its main objectives are to assess safety, how the drug behaves in the body, and suitable doses for subsequent studies, while also exploring preliminary antitumor activity.

The study’s combination treatment has changed: the 2024 announcement originally outlined plans to add pembrolizumab after monotherapy testing. By June 2026, Zumutor and Coherus had announced a collaboration and confirmed that the first patient had been dosed with ZM008 in combination with another PD-1 antibody, toripalimab. This US combination study plans to enroll up to 45 participants across dose-escalation and expansion phases, aiming to explore the effects of simultaneously targeting immune pathways associated with NK cells and T cells.

The positive information available so far still comes mainly from company disclosures. The companies’ June announcement stated that no dose-limiting toxicities or anti-drug antibodies had been observed in the ZM008 monotherapy study at that time. Subsequent reporting by Mint mentioned early clinical signals in patients with renal cell carcinoma. However, these reports did not provide complete participant numbers, response rates, or duration of response sufficient to assess efficacy, and therefore cannot establish that the drug already delivers reliable clinical benefits.

Clinical validation also has implications for the company’s next steps. According to Mint, Zumutor hopes to launch a global Phase 2 study in 2027, including in India, and is seeking regional licensing opportunities. These remain the company’s development and business plans. The existing Coherus collaboration is a clinical trial and drug supply arrangement, with each company retaining commercial rights to its own drug.

For ZM008, the next questions go beyond whether it can activate immune cells to include which patients might benefit, how long the effects might last, and what additional risks the two-drug combination might introduce. The Phase 1 study can help characterize safety and the dose range. Whether releasing the LLT1 brake can translate into meaningful treatment advances for patients remains to be tested in subsequent trials.

References

  1. Zumutor Biologics via PR Newswire